Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

43 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept Study.
Paul S, Williet N, Di Bernado T, Berger AE, Boschetti G, Filippi J, Del Tedesco E, Nancey S, Flourie B, Roblin X. Paul S, et al. Among authors: del tedesco e. J Crohns Colitis. 2018 Aug 29;12(9):1089-1096. doi: 10.1093/ecco-jcc/jjy077. J Crohns Colitis. 2018. PMID: 29860366
Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.
Roblin X, Duru G, Williet N, Del Tedesco E, Cuilleron M, Jarlot C, Phelip JM, Boschetti G, Flourié B, Nancey S, Peyrin-Biroulet L, Paul S. Roblin X, et al. Among authors: del tedesco e. Inflamm Bowel Dis. 2017 Jan;23(1):126-132. doi: 10.1097/MIB.0000000000000986. Inflamm Bowel Dis. 2017. PMID: 28002129
Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months.
Williet N, Boschetti G, Fovet M, Di Bernado T, Claudez P, Del Tedesco E, Jarlot C, Rinaldi L, Berger A, Phelip JM, Flourie B, Nancey S, Paul S, Roblin X. Williet N, et al. Among authors: del tedesco e. Clin Gastroenterol Hepatol. 2017 Nov;15(11):1750-1757.e3. doi: 10.1016/j.cgh.2016.11.023. Epub 2016 Nov 24. Clin Gastroenterol Hepatol. 2017. PMID: 27890854
43 results